High purity Indirubin Cas 479-41-4 

Indirubin is an active ingredient of anti-leukemia isolated from dried leaves of Isatis indigotica Fort. For the treatment of chronic myeloid leukemia, the total effective rate was 87.3%. In terms of reducing white blood cells effect, Indirubin is similar to Maryland, but better than Maryland in reducing liver. Its' blood and bone marrow mitigation effect is worse than Maryland, and has no cross tolenrance with Maryland.

Indirubin also has a certain effect on acute myeloid leukemia. It can be used for abnormal myelopathy and eosinophilia. Indirubin has inhibiting effect on a variety of transplanted animal tumors, and can destroy leukemia cells. With the effect of Indirubin, cells of degeneration and necrosis show swelling and soluble necrosis. Through experimental studies it is found that Indirubin can enhance the animal's monocyte-macrophage system's phagocytosis. Indirubin has no direct effect on protein synthesis. Its' inhibition of DNA synthesis is due to inhibition of DNA polymerase, affecting the polymerization of DNA. Indirubin metabolizes in liver and gallbladder after intravenous injection or intragastric administration. After 96 hours 76.03% Indirubin was eliminated by faeces. After taking this product, the mice's blood concentration gradually increased, after 12 hours it reached the peak, slowed down after a month, maintaining a long time. Indirubin is highly distributed in liver, gallbladder and gastrointestinal. Bioavailability was 46.48%.

Indication

Indirubin has anti-cancer effect. It is clinically used for the treatment of chronic myeloid leukemia.

Usage and Dosage

Adult Dosage: 50 ~ 300mg/day, generally 200mg/day, 3 to 4 times/day by taking orally until symptoms relieved or 3 months for a course of treatment.

Dosage From

Indirubin Tablet: 25mg; 50mg; 100mg.